Highbridge Capital Management LLC lowered its position in shares of Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) by 46.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 40,000 shares of the company’s stock after selling 35,000 shares during the quarter. Highbridge Capital Management LLC owned 0.31% of Spring Bank Pharmaceuticals worth $674,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. Sectoral Asset Management Inc raised its stake in shares of Spring Bank Pharmaceuticals by 9.7% during the 3rd quarter. Sectoral Asset Management Inc now owns 123,383 shares of the company’s stock worth $2,078,000 after purchasing an additional 10,883 shares in the last quarter. Tiedemann Wealth Management LLC raised its stake in shares of Spring Bank Pharmaceuticals by 13.8% during the 3rd quarter. Tiedemann Wealth Management LLC now owns 412,049 shares of the company’s stock worth $6,939,000 after purchasing an additional 50,000 shares in the last quarter. C WorldWide Group Holding A S raised its stake in shares of Spring Bank Pharmaceuticals by 342.6% during the 3rd quarter. C WorldWide Group Holding A S now owns 111,200 shares of the company’s stock worth $1,873,000 after purchasing an additional 86,077 shares in the last quarter. Morse Asset Management Inc raised its stake in shares of Spring Bank Pharmaceuticals by 94.7% during the 3rd quarter. Morse Asset Management Inc now owns 124,000 shares of the company’s stock worth $2,004,000 after purchasing an additional 60,300 shares in the last quarter. Finally, Parsons Capital Management Inc. RI raised its stake in shares of Spring Bank Pharmaceuticals by 2.2% during the 3rd quarter. Parsons Capital Management Inc. RI now owns 281,728 shares of the company’s stock worth $4,744,000 after purchasing an additional 6,000 shares in the last quarter. Institutional investors own 29.70% of the company’s stock.

Shares of Spring Bank Pharmaceuticals Inc (NASDAQ SBPH) opened at $12.13 on Friday. Spring Bank Pharmaceuticals Inc has a 12 month low of $6.31 and a 12 month high of $18.93.

SBPH has been the topic of a number of analyst reports. Cantor Fitzgerald set a $29.00 price objective on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 16th. Chardan Capital reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, November 6th. ValuEngine cut Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Finally, B. Riley initiated coverage on Spring Bank Pharmaceuticals in a research note on Monday, November 6th. They set a “buy” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $27.25.

WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/17/highbridge-capital-management-llc-sells-35000-shares-of-spring-bank-pharmaceuticals-inc-sbph.html.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Want to see what other hedge funds are holding SBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH).

Institutional Ownership by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Stock Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related stocks with our FREE daily email newsletter.